FIELD: biochemistry.
SUBSTANCE: invention relates to use of a synergistic combination in treating non-Hodgkin lymphoma, chronic lymphocytic leukemia or acute lymphoblastic leukemia associated with CD19 expression. Disclosed is a method of treating non-Hodgkin lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia associated with CD19 expression using said synergetic combination.
EFFECT: invention enables effective treatment of lymphoma, chronic lymphocytic leukemia or acute lymphoblastic leukemia associated with CD19 expression.
44 cl, 10 dwg, 32 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION OF CD19 ANTIBODY AND BRUTON TYROSINE KINASE INHIBITOR AND THEIR APPLICATION | 2016 |
|
RU2756010C2 |
| COMBINATION OF CD19 ANTIBODY WITH BCL-2 INHIBITOR AND ITS APPLICATION METHODS | 2017 |
|
RU2756405C2 |
| TREATMENT APPROACH DESIGNED TO TREAT WITH A COMBINATION OF ANTI-CD19 ANTIBODY AND VENETOCLAX | 2018 |
|
RU2802812C2 |
| FORMULATIONS BASED ON CD19 ANTIBODY | 2017 |
|
RU2748024C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2826991C2 |
| ANTI-CD79B ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF | 2020 |
|
RU2817143C2 |
| METHODS AND COMPOSITIONS FOR ADMINISTRATION OF DOSES OF ALLOGENEIC T-CELLS WITH CHIMERIC ANTIGEN RECEPTOR | 2018 |
|
RU2776322C2 |
| ANTI-TRBC1 ANTIGEN-BINDING DOMAIN | 2018 |
|
RU2791327C2 |
| CELL | 2015 |
|
RU2768019C2 |
| ANTIBODIES TO PROTEIN CD38, AND THEIR USE | 2019 |
|
RU2776795C2 |
